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Abstract The Eunethydis ADHD Guidelines group set
out here the ethical principles governing the relationship
between the group and industry. The principles set out here
are provided to ensure that this is both done and seen to be
done. The impetus for these guidelines comes from within
the Group and is linked to the recognition for the need for
an open and transparent basis for Group-industry relations,
especially in the light of the present concern that the
pharmaceutical industry may be exerting a growing
inﬂuence on the actions of researchers and clinicians in the
ADHD ﬁeld.
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Preamble The members of the Eunethydis ADHD Guide-
lines Group (referred to as Group below) are clinicians and
researchers dedicated to the understanding of ADHD/
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DOI 10.1007/s00787-010-0114-8Hyperkinetic Disorder and its effective treatment. Their
role has been to prepare guidelines for the treatment of
ADHD—three such guidelines have so far been published
[1–3]. This clearly raises potential conﬂicts of interest with
the commercial companies who develop and market
treatments for ADHD.
This document sets out the ethical principles governing
the relations between the Group, and its members, and
industry. This is important because many members of the
Group have at one time or another entered into ﬁnancial
relations with pharmaceutical companies for a range of
different activities including consultancy, advice, presen-
tations to meetings, as well as funding for trials and other
studies. The goal of these collaborations varies across
activities but the common element for the Group is that
they are motivated by a desire to improve the under-
standing of ADHD and its treatment and to disseminate
best practice in both research and therapy.
We are conﬁdent that these relations are conducted with
both the highest ethical standards. The principles set out
here are provided to ensure that this is both done and seen
to be done. The impetus for these guidelines comes from
within the Group and is linked to the recognition for the
need for an open and transparent basis for Group–industry
relations, especially in the light of the present concern that
the pharmaceutical industry may be exerting a growing
inﬂuence on the actions of researchers and clinicians in the
ADHD ﬁeld.
Transparency and register of potential conﬂicts of
interest The notion of transparency will be the core prin-
ciple upon which this statement is built. A fully compre-
hensive register of any potential competing interests that
arise out of work with commercial for-proﬁt companies
will be established and maintained by the chair of the
Group. The register will be on a freely available website,
updated twice yearly. This will include a short detailed
description of the activity involved as well as its time-
frame. Examples of relevant activities include; advisory
board membership, consultancy, presentations at company-
funded meetings, travel bursaries and conference atten-
dance support. Both investigator initiated trials and pivotal
phase 3 and phase 4 marketing trials should be declared.
Activities should be declared whether funds are paid
directly to the individual or indirectly, ie to an account
within a university or other organisation. In time, these
principles and procedures may be extended to not-for-proﬁt
organisations. At present, it is not envisaged that these
declarations will include reference to the scale of ﬁnancial
involvement; but this will remain under review. Where
conﬁdentiality is required in these matters, the register of
competing interests should acknowledge the interaction in
a general sense and note the company and product
involved.
Independence of group decision making Members with
interests will declare them whenever relevant products are
discussed; at chair’s discretion they can then discuss
informally, but not vote. Members who have conducted
trials on a particular product will be allowed to present data
to the Group on those trials during the review process.
However, these data will be evaluated by members of the
Group that are independent of these involvements. In case
of conﬂicting opinions about the merits of a study and the
meaning of the results, members involved with a speciﬁc
project will be excluded from making the ﬁnal decision. If
the situation arises (and it has not to date), when all
members of the group are involved in a trial, then the chair
will approach appropriately qualiﬁed experts to give their
evaluation of the trial data. The value of independent sta-
tistical review of procedures and ﬁndings will be explored.
Protection of group members’ interests In order to
protect the interests of members of the group the following
procedures will be established.
1. A register of attempts at undue inﬂuence by companies
on the opinions and activities of Group members will
be established and occasions of such will be placed on
public record.
2. An informal system of peer review will be established
to ensure that documents written or talks prepared for
companies and funded by them conform to these
ethical guidelines.
3. A record will be made of the outcome of this review.
4. Before entering into ﬁnancial arrangements with
industrial interests Group members should make a
disclosure that their conduct is regulated by the
principles set out in this document.
Ethical conduct of group members In order to ensure
that for-proﬁt-related activities are conducted within an
ethical framework the following principles are set down.
1. Company-funded drug trials should be undertaken by
Group members only when there is an agreement that
they have sufﬁcient access to analyses of the data and
that they can be conﬁdent in the integrity of the data
and analyses and there is no in principle veto on
publication of data.
2. Involvement of Group member in ghost written
papers prepared by professional medical writers for
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123companies is prohibited. Furthermore members per-
forming trials for companies are expected to be
independent in their interpretation, able to review all
material before it is published, and responsible for the
whole of a paper of which they are an author. They
should avoid inducements that could lead to bias in
reporting.
3. When presenting data on company-funded trials the
Group member must retain full editorial control and
ensure that they operate in a completely unbiased and
scientiﬁcally balanced way.
4. In relation to data reviewed by the Group for published
guidelines, to ensure consistency and to protect their
interests, a spirit of collective responsibility will be
adopted in which Group members present the agreed
guidelines position. However, this position needs to be
reconciled with the need to maintain the individual
academic freedom of Group members and to respond
to developments in the ﬁeld. Where these amendments
to the published guideline position are made they will
be reported to the Group.
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